Peter Nestler, PhD has over 25 years of experience in academic research and pharmaceutical lead discovery focused on the interplay of disciplines and technologies in the context of understanding and modulating biological processes. He has served in leadership roles since 1995 in academia and industry. He held a faculty position at Cold Spring Harbor Laboratory and has led drug discovery project teams and medicinal chemistry groups. At the global level, he was heavily engaged in the Aventis Chemical Biology Initiative as the leader of the Chemical Biology Proteases platform. He has contributed to a multitude of therapeutic area projects, such as antithrombotics, diabetes, degenerative and inflammatory joint diseases. He has delivered various novel lead drug compounds to the Sanofi pipeline, such as a Factor Xa and a dF508-CFTR corrector.